Abstract

Mini Review

Chemotherapy-induced Peripheral Neuropathy: A Mini-review of Current & Developmental Treatments

Robert Freeze and Scott Scarneo*

Published: 22 February, 2024 | Volume 8 - Issue 1 | Pages: 020-023

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a major limiting side effect of many common chemotherapeutics often leading patients to terminate their chemotherapy treatment regimen early. The development of CIPN differs by chemotherapeutic class, with platinum- and taxane-based treatments demonstrating the highest incidence rates. Despite its relatively high prevalence, there are currently no FDA-approved treatments for CIPN, and clinicians must rely on the off-label use of several analgesics and various non-pharmacological approaches to treat CIPN symptoms in patients. Novel insights on the development of CIPN have identified new drug targets leading to several Phase II clinical trials to be initiated. Here, we describe recent advances in drug development for CIPN.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001093 Cite this Article Read Full Article PDF

Keywords:

Neuropathy; Chemotherapeutics; Drug development

References

  1. Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Crit Rev Oncol Hematol. 2020 Jan;145:102831. doi: 10.1016/j.critrevonc.2019.102831. Epub 2019 Nov 13. PMID: 31783290; PMCID: PMC6982645.
  2. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017 Jun;81(6):772-781. doi: 10.1002/ana.24951. Epub 2017 Jun 5. PMID: 28486769; PMCID: PMC5656281.
  3. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15-49. doi: 10.1053/j.seminoncol.2005.12.010. PMID: 16473643.
  4. Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019 Jun;20(6):769-780. doi: 10.1016/S1470-2045(19)30163-9. Epub 2019 May 8. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346. PMID: 31078462.
  5. A.A.f.C. Cancer in 2023.
  6. Armstrong-Gordon E, Gnjidic D, McLachlan AJ, Hosseini B, Grant A, Beale PJ, Wheate NJ. Patterns of platinum drug use in an acute care setting: a retrospective study. J Cancer Res Clin Oncol. 2018 Aug;144(8):1561-1568. doi: 10.1007/s00432-018-2669-6. Epub 2018 May 22. PMID: 29789926.
  7. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23. PMID: 25261162.
  8. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP, Chan CW, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019 Feb 8;19(1):132. doi: 10.1186/s12885-019-5302-4. PMID: 30736741; PMCID: PMC6368751.
  9. Giraudet F, Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, Cabrespine A, Chaleteix C, Soubrier M, Bay JO, Lemal R, Balayssac D. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study. Eur Arch Otorhinolaryngol. 2022 Apr;279(4):2197-2201. doi: 10.1007/s00405-021-07234-1. Epub 2022 Jan 31. PMID: 35098333.
  10. Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019 Mar 22;20(6):1451. doi: 10.3390/ijms20061451. PMID: 30909387; PMCID: PMC6471666.
  11. Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB. Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy. Curr Treat Options Oncol. 2022 Jan;23(1):29-42. doi: 10.1007/s11864-021-00926-0. Epub 2022 Feb 15. PMID: 35167004; PMCID: PMC9642075.
  12. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clin Cancer Res. 2019 Nov 1;25(21):6295-6301. doi: 10.1158/1078-0432.CCR-18-2152. Epub 2019 May 23. PMID: 31123053; PMCID: PMC6825524.
  13. Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 Apr;60(4):444-452. doi: 10.1002/jcph.1559. Epub 2019 Dec 4. PMID: 31802506; PMCID: PMC7064382.
  14. Brown TJ, Sedhom R, Gupta A. Chemotherapy-Induced Peripheral Neuropathy. JAMA Oncol. 2019 May 1;5(5):750. doi: 10.1001/jamaoncol.2018.6771. PMID: 30816956.
  15. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14. PMID: 32663120.
  16. Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin Drug Investig. 2020 Mar;40(3):249-257. doi: 10.1007/s40261-019-00882-6. PMID: 31925721.
  17. Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, Winquist E, Lock M, Lustberg M, Prsic E. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Support Palliat Care. 2023 Mar;13(1):27-34. doi: 10.1136/spcare-2022-003815. Epub 2022 Sep 8. PMID: 36194493.
  18. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359-67. doi: 10.1001/jama.2013.2813. PMID: 23549581; PMCID: PMC3912515.
  19. Cymbalta FDA Label. (fda.gov).
  20. Lyrica FDA Label (fda.gov).
  21. Dedicated to the Fight Against Disease and Pain. https://us.ono-pharma.com
  22. Boerboom A, Dion V, Chariot A, Franzen R. Molecular Mechanisms Involved in Schwann Cell Plasticity. Front Mol Neurosci. 2017 Feb 17;10:38. doi: 10.3389/fnmol.2017.00038. PMID: 28261057; PMCID: PMC5314106.
  23. ONO-2910-03: An Early Phase II Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect of ONO-2910 in Patients With Breast Cancer Receiving Paclitaxel. . Japan Registry of Clinical Trials JRCT ID: jRCT2031230173.
  24. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002 May;5(5):405-14. doi: 10.1038/nn835. PMID: 11953750.
  25. Novaremed Non Opioid Treatment for Pain. https://www.novaremed.com
  26. AlgoTx Announces Initiation of Global Phase 2 Clinical Trial of ATX01 for the Relief of Pain in Chemotherapy-induced Peripheral Neuropathy in Adults – AlgoTx. 2022.
  27. gov is a database of privately and publicly funded clinical studies conducted around the world. NCT05593614
  28. Naznin F, Waise TMZ, Fernyhough P. Antagonism of the Muscarinic Acetylcholine Type 1 Receptor Enhances Mitochondrial Membrane Potential and Expression of Respiratory Chain Components via AMPK in Human Neuroblastoma SH-SY5Y Cells and Primary Neurons. Mol Neurobiol. 2022 Nov;59(11):6754-6770. doi: 10.1007/s12035-022-03003-1. Epub 2022 Aug 25. PMID: 36002781; PMCID: PMC9525428.
  29. A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy. NCT05488873.
  30. Sonnet Biotherapeutics. www.sonnetbio.com/pipeline.
  31. SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN). NCT05435742
  32. English K, Barton MC. HDAC6: A Key Link Between Mitochondria and Development of Peripheral Neuropathy. Front Mol Neurosci. 2021 Aug 31;14:684714. doi: 10.3389/fnmol.2021.684714. PMID: 34531721; PMCID: PMC8438325.
  33. Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. doi: 10.3390/ph3092751. PMID: 27713375; PMCID: PMC4034096.
  34. A Study to Investigate the Safety and Efficacy of Ricolinostat. NCT05229042.
  35. Weigert A, Olesch C, Brüne B. Sphingosine-1-Phosphate and Macrophage Biology-How the Sphinx Tames the Big Eater. Front Immunol. 2019 Jul 19;10:1706. doi: 10.3389/fimmu.2019.01706. PMID: 31379883; PMCID: PMC6658986.
  36. Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LA, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A, Spiegel S, Neumann WL, Vanderah TW, Salvemini D. Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. Proc Natl Acad Sci U S A. 2019 May 21;116(21):10557-10562. doi: 10.1073/pnas.1820466116. Epub 2019 May 8. PMID: 31068460; PMCID: PMC6534990.
  37. Salvemini D, Doyle TM. Targeting neuroinflammation in neuropathic pain and opioid use. J Exp Med. 2023 Feb 6;220(2):e20221244. doi: 10.1084/jem.20221244. Epub 2022 Dec 23. PMID: 36562735; PMCID: PMC9793426.
  38. Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, Esposito E, Cuzzocrea S, Bieberich E, Obeid L, Petrache I, Nicol G, Neumann WL, Salvemini D. The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J Biol Chem. 2014 Jul 25;289(30):21082-97. doi: 10.1074/jbc.M114.569574. PMID: 24876379; PMCID: PMC4110312.
  39. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019 Apr 1;20(2):273-286. doi: 10.1093/biostatistics/kxx069. Erratum in: Biostatistics. 2019 Apr 1;20(2):366. PMID: 29394327; PMCID: PMC6409418.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?